Essential Pharmaceuticals Releases New Study on Cell-Ess Media. Increase in Antibody Titer and Improved Glycosylation Confirmed.
EWING, N.J., May 31, 2017 /PRNewswire/ -- Cell-Ess® media from Essential Pharmaceuticals, LLC has been shown to increase antibody titer and improve glycosylation in a new bioproduction study. Cell-Ess is a chemically-defined and animal component free supplement and feed that delivers critical components, including essential fats, needed for cell growth. As a feed, Cell-Ess has been used in different CHO cell backbones and media formats to consistently improves protein titer by >20% compared to control as shown in a recent peer-reviewed publication. In a new study, Cell-Ess demonstrated an ability to improve glycan pattern consistency and complexity while also increasing titer.
The biologics industry is growing, and there are pressures to reduce the costs associated with bioprocessing and thereby reduce the price of the drugs to patients. One way to address production costs is by increasing the efficiency of the cell "factories" through increasing the yield of therapeutic proteins. However, efficacy of a drug is critical, and product quality attributes are used to determine if a biologic will meet the efficacy requirements. Sometimes a tradeoff is made where lower yields are accepted in order to assure that critical quality attributes, such as glycosylation profiles, remain within specification. There are multiple factors that drive glycosylation and several currently available approaches to influence glycosylation patterns. One relatively unexplored lever to influence glycosylation patterns is the addition of lipids (cholesterol and fatty acids) to culture media. Multiple studies demonstrate the numerous challenges of adding lipids to culture, specifically in single-use systems.
Cell-Ess has consistently demonstrated the ability to increase antibody productivity when added as a feed or supplement to previously optimized systems. The increase was observed on a per cell basis, which means that downstream scientists do not have additional biomass to purify. Additionally, the increase is scalable to bioreactors, including single-use bioreactors.
"Cell-Ess used as a feed in an ambr® system increased protein productivity by >20% when added to multiple basal media," says Dr. Adam Elhofy, CSO of Essential Pharmaceuticals. "In addition, cells that received Cell-Ess demonstrated improved glycosylation consistency and a shift from lower order glycoforms to higher order glycoforms."
"Biopharmaceutical companies cannot afford to sacrifice therapeutic quality for protein titer, even if increased titer leads to improved operational efficiencies," says Allan Weber, CEO. "Cell-Ess has repeatedly demonstrated that it increases titer while improving glycosylation, providing a unique solution to manufacturers looking to reduce cost of goods sold."
About Essential Pharmaceuticals
Essential Pharmaceuticals provides surgeons, medical researchers, and manufacturers new tools to bring performance, convenience, and control to enhance the advancement of basic research and drug discovery. Established in 2006, Essential Pharmaceuticals supports the preservation and growth of human systems through expanding its product development to further medical treatments for mankind.
For more information, visit www.EssentialPharma.com or contact Denise Weber at the corporate office: 1-844-Ess-Prod Email: [email protected]
SOURCE Essential Pharmaceuticals
Share this article